Opioid Safety: US FDA Hears Mixed Messages On Adding Posmarketing Studies To Labeling

 
• By Sue Sutter
Mixed messages
The FDA heard a variety of advice on what to do with opioid postmarketing study results. (Shutterstock)

More from US Advisory Committees

More from Post-Marketing Regulation & Studies